Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
Price:
3.89 CNY
-1.27%
Market Closed
Updated:
May 18, 2024
P/S
Price to Sales
Price to Sales
1.2
Current
1.5
Median
2.5
Industry
Lower
than median
Lower
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=1.2
Market Cap
/
7.5B
Revenue
6.4B
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| CN |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
|
7.5B CNY | 1.2 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
731.8B USD | 20.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.5 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
372.2B USD | 4.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
332.3B USD | 5.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.7B GBP | 5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
189B CHF | 3.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.7B CHF | 3.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.7B USD | 2.9 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
0.9
2-Years Forward
P/S
0.9
3-Years Forward
P/S
N/A
You don't have any saved screeners yet
